NCT00562952View on ClinicalTrials.gov

Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Diabetes MellitusHeart FailureCoronary Artery Disease
Interventions
DRUG

Telmisartan, Bisoprolol

Dosage will be given dependent on the NT-pro-BNP levels. Up-titration will be performed until values are decreased to 50% or below normal cut-point

DRUG

placebo

no intervention

Trial Locations (2)

1090

General Hospital of Vienna Department of Endocrinology, Vienna

Medical University of Vienna, Vienna

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Medical University of Vienna

OTHER

NCT00562952 - Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients | Biotech Hunter | Biotech Hunter